Kikuyo Sakaguchi agreed to acquire remaining 30% stake in Immunokick Inc. from Trans Genic Inc. (TSE:2342) for ¥3 million on July 22, 2016. A share transfer contract is expected to be signed on July 22, 2016. Kikuyo Sakaguchi is the Representative Director and President of Immunokick. Kikuyo Sakaguchi will acquire remaining 60 shares. As of March 31, 2016, Immunokick Inc. reported net assets of ¥1.4 million, total assets of ¥16.23 million, sales of ¥12.12 million, operating profit of ¥1.03 million and net income of ¥1.41 million. The deal is expected to be closed by September 30, 2016.